Top Abstract Purchase Related
Home
>
Node
>
Subnode

Hyperhomocysteinemia as a risk factor for venous thrombosis

Willems, H.P.; den Heijer, M.; Blom, H.J.; Gerrits, W.B.; Rosendaal, F.R.; Bos, G.M.

Nederlands Tijdschrift Voor Geneeskunde 143(11): 552-556

1999

ISSN/ISBN: 0028-2162
PMID: 10321272
Document Number: 503873
In recent years research was done to elucidate the relation between an increased homocysteine concentration and arterial as well as venous thrombosis. Several case control studies showed that an elevated homocysteine concentration is an independent risk factor for primary and secondary venous thromboembolism. It is not clear whether lowering homocysteine levels by administration of folic acid, whether or not in combination with vitamin B12 and vitamin B6, decreases the risk of vascular events. Randomized secondary prevention trials are being conducted at this moment. It is recommended to await the results of these trials before screening for and treating of individuals with hyperhomocysteinaemia.

Document emailed within 1 workday
Secure & encrypted payments

Martinelli, I.; Landi, G.; Merati, G.; Cella, R.; Tosetto, A.; Mannucci, P.M. 1996: Factor V gene mutation is a risk factor for cerebral venous thrombosis Thrombosis and Haemostasis 75(3): 393-394
Dahlbäck, B. 1997: Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis Thrombosis and Haemostasis 78(1): 483-488
Alessandrello Liotta, A.; Marcucci, R.; Bialek, W.; Poli, D.; Ilari, I.; Fedi, S.; Cellai, A.P.; Rogolino, A.; Prisco, D.; Abbate, R. 1999: Lp(a): a new risk factor for deep venous thrombosis? Minerva Cardioangiologica 47(12): 529
Agarwal, M.B.; Manocha, S. 2000: Acquired hyperhomocysteinemia, megaloblastosis with subacute combined degeneration and deep venous thrombosis Journal of the Association of Physicians of India 48(5): 545-546
Castaman, G.; Faioni, E.M.; Tosetto, A.; Bernardi, F. 2003: The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis Haematologica 88(10): 1182-1189
Schlosser, U.; Lackner, K.J.; Scheckenhofer, C.; Spannagl, M.; Spengel, F.A.; Hahn, G.; Lang, B.; Schmitz, G. 1997: Autoantibodies against the protease inhibitor calpastatin: a new risk factor for venous thrombosis? Thrombosis and Haemostasis 77(1): 11-13
Minnee, R.C.; Middeldorp, S.; Legemate, D.A. 2009: Malformation of the V. cava inferior, a risk factor for deep venous thrombosis Nederlands Tijdschrift Voor Geneeskunde 153(11): 496-500
Koopman, K.; Uyttenboogaart, M.; Vroomen, P.C.A.J.; van der Meer, J.; De Keyser, J.; Luijckx, G-Jan. 2009: Risk factors for cerebral venous thrombosis and deep venous thrombosis in patients aged between 15 and 50 years Thrombosis and haemostasis 102(4): 620-622
Keijzer, M.B.A.J.; den Heijer, M.; Blom, H.J.; Bos, G.M.J.; Willems, H.P.J.; Gerrits, W.B.J.; Rosendaal, F.R. 2002: Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis Thrombosis and Haemostasis 88(5): 723-728
Reuner, K.H.; Ruf, A.; Grau, A.; Rickmann, H.; Stolz, E.; Jüttler, E.; Druschky, K.F.; Patscheke, H. 1998: Prothrombin gene G20210-->A transition is a risk factor for cerebral venous thrombosis Stroke 29(9): 1765-1769
Saadatnia, M.; Naghavi, N.; Fatehi, F.; Zare, M.; Tajmirriahi, M. 2012: Oral contraceptive misuse as a risk factor for cerebral venous and sinus thrombosis Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences 17(4): 344-347
Tichelaar, Y.I.G.V.; Lijfering, W.M. 2015: Is hyperhomocysteinaemia a minor risk factor for venous thrombosis or subject to publication bias? Netherlands Journal of Medicine 73(8): 394-395
Kapur, R.; Stramrood, C.A.I.; Schutgens, R.E.G.; van Asbeck, B.Sweder. 2009: Cyproterone acetate- and ethinyloestradiol-containing oral contraceptive as a risk factor for upper extremity deep venous thrombosis-a case report European Journal of Contraception and Reproductive Health Care: the Official Journal of the European Society of Contraception 14(2): 160-163
Kleesiek, K.; Schmidt, M.; Götting, C.; Schwenz, B.; Lange, S.; Müller-Berghaus, G.; Brinkmann, T.; Prohaska, W. 1999: The 536C-->T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis Thrombosis and Haemostasis 82(1): 1-5
Cafagna, D.; Ponte, E. 1997: Hyperhomocysteinemia: a new independent vascular risk factor? Minerva Cardioangiologica 45(1-2): 49-55
Herrmann, W.; Jean-Pierre Knapp 2002: Hyperhomocysteinemia: a New Risk Factor for Degenerative Diseases Clinical Laboratory 48(9-10): 411-481
Sharma, S.K.; Gupta, V.; Kadhiravan, T.; Banga, A.; Seith, A.; Kumar, A.; Saxena, R.; Thabah, M.M.; Gulati, V.; Bhatia, I.; Kavimandan, A.A. 2009: A prospective study of risk factor profile and incidence of deep venous thrombosis among medically-ill hospitalized patients at a tertiary care hospital in northern India Indian Journal of Medical Research 130(6): 726-730
Chauveau, P.; Chadefaux, B.; Coudé, M.; Aupetit, J.; Hannedouche, T.; Kamoun, P.; Jungers, P. 1993: Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients Kidney International. Suppl 41: S72-S77
Rosendaal, F.R. 1997: Thrombosis in the young: epidemiology and risk factors. a focus on venous thrombosis Thrombosis and Haemostasis 78(1): 1-6
Horbach, D.A.; van Oort, E.; Donders, R.C.; Derksen, R.H.; de Groot, P.G. 1996: Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies Thrombosis and Haemostasis 76(6): 916-924